We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test (REPHRASE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05107882
Recruitment Status : Not yet recruiting
First Posted : November 4, 2021
Last Update Posted : November 4, 2021
Sponsor:
Collaborators:
Eastern Virginia Medical School
Cleveland Clinic Lou Ruvo Center for Brain
Ottawa Memory Clinic
Clinique Memoire de L'Outaouais
University of Washington
Information provided by (Responsible Party):
Optina Diagnostics Inc.

Brief Summary:
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC (K200254).

Condition or disease
Alzheimer Disease Mild Cognitive Impairment Mild Dementia

Detailed Description:
This non-interventional, cross-sectional study is designed to validate a novel diagnostic test, the Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) test, for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (positive or negative). The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC for imaging the retina. The study objective is to characterize the performance of the diagnostic CAS test in the target population of adult patients fifty (50) years and older with cognitive impairment, who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. The data generated in this study will provide evidence to be used in the assessment of the benefits and risks associated with use of the device in the intended population. The primary endpoint is to demonstrate accuracy of the Optina Diagnostics' CAS test compared to amyloid-PET status, as determined by a majority of three (3) qualified, independent PET Readers.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Retinal Deep PhenotypingTM Platform for Cerebral Amyloid Status Evaluation: a Validation Study
Estimated Study Start Date : November 2021
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis




Primary Outcome Measures :
  1. Retinal beta-amyloid detection [ Time Frame: 1 year ]
    Presence of absence of beta-amyloid plaques in the retina where the accuracy will be assessed using positive percent agreement (PPA) and negative percent agreement (NPA) with 95% confidence intervals.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The target population for the Optina Diagnostics' CAS test is men and women 50 years and older who are under clinical investigation for cognitive impairment where Alzheimer's disease (AD) is one of the possible differential diagnoses.

As concomitant eye pathologies or conditions could interfere with CAS algorithm, individuals with certain ocular pathologies or conditions, including glaucoma, age-related macular degeneration (AMD), retinopathies, and advanced cataracts, will not be included in the target population at this time. Work is on-going to improve the CAS classifier algorithm with the goal to include these individuals in the target population at a later date.

Criteria

Inclusion Criteria:

  • Male and female adults aged 50 years and older (inclusive).
  • Individuals with reported cognitive complaint (self or from an informant) under clinical investigation by a health professional for cognitive impairment where Alzheimer's disease (AD) is one of the differential diagnoses.
  • Demonstrated cognitive impairment as evidenced by at least one of the following:

    1. Mini Mental State Examination (MMSE) score < 26/30
    2. Montreal Cognitive Assessment (MoCA) score < 26/30
    3. Score > 1 Standard Deviation below population mean on a standardized neuropsychological test (in any domain), based on normative data from age-, sex-, education-, and where possible, race-matched peers [Based on guidelines for detecting Mild Cognitive Impairment due to AD (Albert et al., 2011)]
  • Clinical laboratory assessment (complete blood count [CBC], standard blood chemistry profile, thyroid stimulating hormone [TSH], vitamin B12) within the 6 months prior to enrollment.
  • Cognitive impairment on the above test/s is unable to be fully explained by systemic, neurological or psychiatric disorders other than Alzheimer's disease.
  • Capacity to give informed consent by patient or substitute decision maker.
  • Ability to undergo PET and MRI scans.

Exclusion Criteria:

  • Any ophthalmologic condition that would prevent obtaining retinal imaging and/or could interfere with the analysis of the MHRC images by the CAS, including:

    1. Pupil dilation contraindicated (due to a pathology, or presence of 3 quadrants with Van Herick grading of 0 or 1 without iridotomy)
    2. Inadequate pupil dilatation (< 6mm diameter) preventing uniform illumination of the retina with the MHRC
    3. Diagnosis of glaucoma or signs of glaucoma (excavation ratio ≥0.7)
    4. Signs of vascular occlusion or retinopathy (microaneurysm, exudate, hemorrhage or edema) within a diameter of 10 mm from the mid-point between the optic nerve head and the macula
    5. Presence of drusen and/or age-related macular degeneration (AREDS 9-step scale ≥4 - cumulative drusen area diameter ≥ 250 um, pigmentary changes and cumulative drusen area diameter ≥ 63 um or pigmentary changes and cumulative geographic atrophy area diameter ≥ 354 um)
    6. Macular anomaly (e.g., macular hole, dystrophy, degeneration)
    7. Nuclear sclerosis > 2 (LOCS II four-point grading system) or presence of central cortical or central posterior subcapsular cataract
    8. Refractive error outside the range of -15 D to +15 D
    9. Scar, atrophy, naevus, tumor, eepiretinal membrane or retinal pucker with a cumulative area > 1 disc area within a diameter of 10 mm from the mid-point between the optic nerve head and the macula
    10. Papilledema
    11. Deficient visual fixation (inability to fixate for at least 2 s)
    12. Corneal or media opacities (e.g., Weiss ring) affecting retinal imaging on a cumulative area > 1 disc area within a diameter of 10 mm from the mid-point between the optic nerve head and the macula (i.e., the area of interest for the MHRC imaging)
  • Inability of obtaining at least 3 images of satisfactory quality with the MHRC per the Optina Diagnostics quality index software and /or per the eye specialists' evaluation.
  • Impossibility of obtaining a satisfactory quality amyloid-PET scan for interpretation by imaging specialists.
  • Individuals who currently or have previously taken cerebral amyloid modifying medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05107882


Contacts
Layout table for location contacts
Contact: Shannon Campbell 5148894994 scampbell@optinadx.com
Contact: Julie Antonelle Orellina, MD 4387225180 jorellina@optinadx.com

Sponsors and Collaborators
Optina Diagnostics Inc.
Eastern Virginia Medical School
Cleveland Clinic Lou Ruvo Center for Brain
Ottawa Memory Clinic
Clinique Memoire de L'Outaouais
University of Washington
Investigators
Layout table for investigator information
Principal Investigator: Hamid Okhravi, MD, PhD FRPC Eastern Virginia Medical Center
Principal Investigator: Richard Bergeron Ottawa Memory Clinic and Clinic Memoire Outaouais
Principal Investigator: Charles Bernick, MD, MPH University of Washington
Principal Investigator: Aaron Ritter, MD Cleveland Clinic Lou Ruvo Center for Brain
Layout table for additonal information
Responsible Party: Optina Diagnostics Inc.
ClinicalTrials.gov Identifier: NCT05107882    
Other Study ID Numbers: DOC100464
First Posted: November 4, 2021    Key Record Dates
Last Update Posted: November 4, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders